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Resveratrol (Res), a natural polyphenol compound found in grapes and red wine 
has been shown to exhibit anti-tumor, anti-oxidant and anti-inflammation effects. 
However, the molecular targets as well as mechanisms of action contributing to the health 
promoting effects of Res are largely unknown. In our study, through dietary or 
pharmaceutical consumption levels, we investigated the effects of Res on inflammation-
driven immune responses in human THP-1 monocytes and human Phorbol 12-myristate 
13-acetate (PMA) differentiated THP-1-derived (P-THP-1) macrophages. Our results 
showed that Res induced anti-proliferation in THP-1 monocytes with S phase arrest at 
dietary concentrations, and, however, induced cell apoptosis and caused G0/G1 phase 
arrest at pharmaceutical concentrations. In addition, Res showed different effects on pro-
inflammatory cytokines in different cell lines. Furthermore, similar analysis on 
pterostilbene and genistein revealed the possible effect was attributed to specific stilbene 
structure. In conclusion, resveratrol and pterostilbene appeared to play different roles of 
inflammatory response in THP-1 and P-THP-1 cells.  
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Chapter 1 Literature review 
1.1 Inflammation 
1.1.1 Immunology and inflammation 
Inflammation is a complicated biological process that regulates the vascular 
tissues’ defense against harmful stimuli, such as pathogens, damaged cells, signals or 
irritants. In ancient Rome, Cornelius Celsus first recorded the signs of inflammation in 
his book “De Medicina”. Four symptoms of inflammation were noted: redness and 
swelling with heat and pain [1]. Later on Rudolf Virchow added “loss of function” for 
inflammation, as well as “inherently pathological reaction”, many centuries later [2]. 
Nowadays, it is considered as nonspecific/innate immune response, compared to adaptive 
immunity, which can be caused by trauma, chemical agents, thermal extremes of heat or 
cold, and pathogenic organisms. The symptoms of inflammation include: increased blood 
flow, elevated cellular metabolism, vasodilatation, release of soluble mediators, 
extravasation of fluids and cellular influx. Without inflammation, infections would go 
without checked, wounds would never heal, and injured tissues would remain damaged.  
 
Acute and chronic inflammation 
Inflammation includes: acute and chronic one. When facing exogenous pathogens, 
acute inflammation is the first response of our body. The inflammatory response has a 
cascade of biochemical events in vascular system and the injured tissues, which may last 
a few minutes to a few days. After the injured site is healed, anti-inflammatory cytokines 
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work to end the inflammation. Nevertheless, chronic inflammation leads to an endless 
inflammation and tissue destruction resulted from enhanced expression of pro-
inflammatory cytokines [3]. One difference between acute inflammation and chronic 
inflammation is that injured tissues are infiltrated by mainly neutrophils within 24 to 48 
hours in acute inflammation, whereas chronic inflammation is more associated with 
monocyte differentiated macrophages and lymphocytes [4].  
 
Innate and adaptive immune response 
According to the book of “Kuby immunology” written by Thomas J. Kindt [5], 
there are two kinds of immune response: innate and adaptive. To protect our body from 
outside invasion by pathogenic microbes and toxins, our immune system has evolved 
well to defend against them. Different reaction and duration time, reaction cell types, and 
specificity for variable types of pathogens have been noted between innate and adaptive 
immune responses. 
The innate immune system is the first line of defense to protect the host from 
pathogens, which is mediated by phagocytes (monocytes, macrophages and dendritic 
cells), which reacts in a couple minutes or hours. The main components of the innate 
immune system are physical epithelial barriers (e.g., skin, anti-microbial compounds), 
phagocytic leukocytes, dendritic cells and natural killers (NK). Antigen-presenting cells 
(APCs) like macrophages and dendritic cells from innate immune system then display a 
fragment of the antigen from engulfed pathogens, which will initiate the adaptive 
immune response. Compared with the innate immune response, adaptive immune 
response is mounted after several days of specific antigenic challenges. If innate 
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immunity is like a key to open a building, adaptive immunity is like a key to open a 
specific door. The adaptive immune response can be further divided into two subgroups: 
humoral immunity (B lymphocytes) and cell-mediated immunity (T lymphocytes). B-
cells are produced and matured in bone marrow. When they leave the bone marrow, each 
B cell expresses a specific antigen-binding receptor on the membrane, which can 
recognize antigen alone. The principal functions of B-cells are to 
make antibodies against antigens, to perform the role of APCs, and to develop into 
memory B-cells after activation by antigen interaction. Unlike B lymphocytes, T 
lymphocytes are produced in the bone marrow, and then migrate to thymus gland to 
mature. T-cells response to major histocompatibility complex (MHC) I or II to perform 
either cell-killing or secreting cytokines functions, respectively. T-helper (TH) cells 
display CD4 and are activated by recognizing and interacting with an antigen-MHC class 
II molecule complex, which becomes an effector cell to secret various cytokines for the 
activation of other immune cells. On the other hand, T cytotoxic (TC) cells, another type 
of T cells, display CD8, which can recognize antigen-MHC class I molecule complex. 
Once initiated, TC cells proliferate and differentiate into cytotoxic T lymphocytes (CTLs). 
The CTLs have a vital function in monitoring the cells of the body and eliminating any 
that display antigen, such as virus-infected cells, tumor cells, and cells of a foreign tissue 
graft [6].  
 
Pathogen recognition and TLR signaling pathway 
Innate immune system is capable of mounting a non-specific response when 
compared with adaptive immune system. However, innate immunity is not completely 
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nonspecific, rather it can recognize conserved limited number of germline-encoded 
pattern-recognition receptors (PRRs) [7]. PRPs are able to: 1) recognize pathogen-
associated molecular patterns (PAMPs), which are small molecular motifs essential and 
conserved for the survival of the microorganism; 2) detect the pathogens and express 
constitutively in the host all through the life cycle; 3) express on all the cells with certain 
type, which are independent of immunologic memory.   
PRRs are found as membrane-bound, cytoplasmic and secreted forms. The Toll-
like receptor (TLR) family, one of PRRs, plays an important role in innate immunity. 
TLRs are trans-membrane proteins, which can recognize extracellular or endosome 
PAMPs and initiate cascade-signaling pathways. To date, there are 10 members of TLRs 
found in humans and 13 in mice. TLRs are expressed on macrophages, dendritic cells, B 
cells, and some types of T cells, fibroblasts and epithelial cells. Several different kinds of 
TLRs can recognize related PAMPs. For example, TLR1, TLR2, TLR4, TLR5, TLR6, 
TLR9, TLR11 can recognize bacteria; TLR2, TLR4, TLR6 can recognize fungus; TLR2, 
TLR4, TLR9, TLR11 can recognize parasites; and TLR2, TLR3, TLR4, TLR7, TLR8, 
TLR9 can recognize viruses. Interestingly, the same TLR can also recognize several 
uncommon ligands. TLR4 plays important role in immune system in that it can recognize 
diversified ligands such as lipopolysaccharide (LPS) from gram-negative bacteria, 
mannan of fungus, glycoinositol phospholipids from parasite, envelop proteins of 
respiratory syncytial virus, heat-shock proteins and fibrinogen, which have different 
structural features [7]. TLRs then activate downstream signaling pathway to induce 
inflammatory cytokines, like TNF-α, IL-1β, IL-6, IL-12 and other effect mediators to 
work against different kinds of pathogens [8].  
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Cellular mediators of inflammation  
Cytokines are part of a category of signaling molecules (non-antibody proteins) 
that mediate and regulate cell growth, immunity, inflammation, hematopoiesis, tissue 
repair, and many other cellular processes forming a cytokine network.  
They were mediators and regulators among immune response, but now many 
cytokines are found to either be produced by non-immune cells or induce effects on non-
immune cells. The cytokines released by a certain type of cells and then bind to specific 
receptors on target cells, where cellular response may take several hours to produce new 
mRNA and synthesis protein. The target cells can be divided into three groups: autocrine 
(target is the same cell), paracrine (nearby cells), and endocrine (distant cells running 
through the circulation).  
The term of cytokine is a general name for those proteins, whereas it can be 
categorized in different groups based on different function and purpose. Monokines are 
those cytokines produced from monocytes and macrophages, and lymphokines come 
from lymphocytes.  
Interleukins are a group of proteins secreted primary from helper T lymphocytes, 
monocytes, macrophages and endothelial cells. Interleukin1 to 36 act significantly as 
signaling molecules through cells in immune systems to regulate cell growth, 
differentiation and motility of T, B and hematopoietic cells, whereas excess or deficient 
interleukins may be involved in autoimmune diseases or immune deficiency, respectively 
[9]. Interleukins are released quickly out from inside of the cells, and travel to target cells 
for further proliferation and activation or regulation, which is a rapid cascade signaling 
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process to initiate other cell’s behavior. IL-1 is secreted from monocytes, macrophages, B 
cells and DCs, and targets on T-helper cells for co-stimulation, B-cells for proliferation, 
and NK cells for activation. Small amount of IL-1 induce acute inflammation, whereas 
large amount may give rise to fever. IL-6 is a key interleukin expressed in both acute 
inflammation and chronic inflammation. In acute inflammation, IL-6 is secreted from the 
site of inflammation to mediate the reaction. When in chronic inflammation, IL-6 plays 
key role to attract mononuclear cell accumulation through MCP-1 secretion by activating 
gp130 in which the transition of acute inflammation to chronic inflammation is from 
neutrophils reaction to monocyte recruitment [10].  
TNF refers to a family of tumor necrosis factors, which can cause cell apoptosis 
with nineteen cytokines included [11]. The two main TNF family cytokines are TNF-α 
and TNF-β.TNF-α is mainly secreted by monocytes or macrophages and functions 
through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine acts as 
pro-inflammatory cytokine, which is involved in the regulation of cell proliferation, 
differentiation, apoptosis, lipid metabolism, and coagulation. Like IL-6, TNF-α is an 
endogenous pyrogen causing fever and other inflammation symptoms, which is also 
implicated in tumor regression, septic shock, and cachexia [12]. On the other hand, TNF-
β, derived from Th1 type T-cells, secretes for the induction of change of surface adhesion 
molecules on certain cells to allow them to bind to phagocytes during inflammation [13].  
Chemokines are a group of signaling cytokines of small sizes (8-10 kilo Daltons) 
featuring in recruiting leukocytes to places of inflammation. They mediate immune cells’ 
trafficking. Their name is formulated because they induce chemotaxis to target cells, so 
they are also called chemotactic chemokines. There are four cysteine residues forming 
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their conservative three-dimensional structure. Some chemokines are pro-inflammatory 
and they can be induced during an immune response to recruit cells of the immune 
system to a site of infection, whereas some other chemokines can control the migration of 
cells during normal processes of tissue maintenance or development.  
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Table 1. Cytokines and functions [14] 
Cytokines Cell source Response to Functions 
IL-1β Macrophages T-cells, B-cells, 
Endothelialcells 
1. T-cell activation 
2. Endogenous pyrogen 
3. B-cell maturation and 
proliferation 
4. Fibroblast growth factor 
activity 
IL-2 Th1 cells CD8 T-cells, B-
cells, NK 
1. T and B-cell proliferation 
2. Stimulate monocytes, 
lymphokine-activated killer 
cells, natural killer cells, and 
glioma cells 
 
IL-3 Activated Th 
cells 
Bone marrow stem 
cells 
Stimulates progenitor cells of 
most cell lineages in bone 
marrow 
IL-4 Th2 cells B-cells 1. B-cell growth 
2. Isotype switching to IgE and 
mast cell proliferation 
3. Th2 induction and MHC-II 
induction on B-cells 
4. T-cell growth factor 
IL-5 Th2 cells B-cells, 
Eosinophils 
 
1. B-cell differentiation 
2. Main regulator of 
eosinopoiesis, eosinophil 
maturation and activation 
IL-6 Th cells, 
Macrophages 
B-cells 1. Inflammation and maturation 
of B-cells 
2. Endogenous pyrogen 
IL-8 Macrophages Neutrophils 1. CXC chemokine family 
2. Attracts neutrophils, 
basophils, and T-cells, but not 
monocytes 
3. Neutrophil activation 




1. Suppress Th1 cells, MHC 
class-II Ags 
2. Co-stimulatory molecules on 
macrophages 
3. Enhance B-cell survival, 
proliferation, and antibody 
production 
4. Block NF-kappa B activity, 
and involve in the regulation of 
the JAK-STAT signaling 
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pathway 
IL-12 APCs Th1 Induces Th1 cells 
IL-15  Non-T-cell 
w/MHC I/II 
cells 
T-cells and NK 1. Activates Th and NK 
2. Stimulation by IL-15 requires 
interaction of IL-15 with 
components of IL-2R, including 
IL-2R beta and probably IL-2R 
gamma but not IL-2R alpha 
IFN-γ Th1 cells Macrophages, B-
cells, T-cells 
1. Inhibits IL-4 effects 
2. Activates macrophages-
promotes cellular response 
3. Inhibition of Th2 responses 
4. Terminal plasma cell 
differentiation 
TGF-β Th1 cells B-cells, T-cells, 
Macrophages 
1. IgA class switching 
2. Inhibits IL-4 
3. Is chemotactic for T-cells and 
Macrophages 





1. Mediator of Septic shock in 
high concentration 
2. T-cell activation 
3. Pyrogen 






Enhances Macrophages and 
neutrophil activity 
MIP-1 Macrophages T-cells, monocytes 1. Chemotactic factor that 
attracts T-cells and monocytes, 
but not neutrophils, eosinophils, 
or B-cells 





1. Monocyte chemotactic 
protein 
2. CC type chemo 
IP-10 and 
MIG 
Macrophages T-cells CXC chemokines that affect T-
cell recruitment 
IL, interleukin; Ags, antigens; Th, helper T cells; APCs, antigen-presenting cells; 
IFN, interferon; NK, natural killer; IP, interferon- γ inducible protein; GM-CSF, 
granulocyte-macrophage colony-stimulating factor; MCP, monocyte chemotactic 
protein; MIG, monokine induced by IFN- γ; MIP, macrophage inflammation 
protein; TNF, tumor necrosis factor; 
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1.2 Resveratrol and its protective effect 
1.2.1 Resveratrol 
Resveratrol (3, 5, 4’ –trihydroxy-trans-stilbene) is a phytoalexin found in a 
variety of foods (e.g., grapes, peanuts, red wine, and berries) in response to 
environmental stress, injury, UV irradiation, and fungal infection. Resveratrol (Res) has 
been shown to exert anti-oxidant, anti-cancer and anti-inflammatory effects [15, 16, 17]. 
Res is also known as 3, 4’, 5-stilbenetriol in cis and trans isometric forms (trans-isoform 
is more widely investigated).  
 




   C 
 








Figure 1. Chemical structure of (A) trans-resveratrol, (B) cis-resveratrol, (C) 
dihydroresveratrol, (D) trans-piceid, (E) resveratrol-O-glucuronide, (F) resveratrol-sulfate 
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Furthermore, piceid was considered as a resveratrol alternative because trans-
piceid can be enzymatically hydrolyzed to trans-Res in the colon or inside enterocytes 
(the same for cis-piceid which can be converted to cis-Res) [18]. Piceid, is named as 
resveratrol 3-O-β-D-glucoside, and is the main component of the Polygonumcuspidatum 
root, used in Chinese and Japanese traditional medicine for treating some chronic 
inflammation disease, and also naturally exists in wine and fruit juice. Interestingly, there 
is higher level of piceid than resveratrol in grape juice. The average concentrations were 
3.38 mg/L for trans-piceid, 0.79 mg/L for cis-piceid, 0.50 mg/L for trans-resveratrol, and 
0.06 mg/L for cis-resveratrol in red grape juice [31]. Through metabolism in humans, 
around 60% trans-piceid may be converted to trans-resveratrol in the body [31].  Hence, 
drinking wine is similar to drinking grape juice on the effect of resveratrol manner.  
1.2.2 Food source 
Resveratrol comes from peanuts, grape skins, strawberry, blueberry, mulberry, 
cocoa powder, as well as Japanese knotweed. From Dr. Baur’s review on resveratrol [16], 
higher contents of trans-res were listed here: red wines with 0.1-14.3 mg/L trans-Res; 
white wines with less than 0.1-2.1 mg/L trans-Res; red grape juice with 0.5 mg/mL; 
cranberry raw juice with 0.2 mg/mL; boiled peanuts with 5.1 µg/g; dark chocolate with 2 
µg/g [19]; and rhubarb dry root with 3.9 mg/g (Chinese medicine). Dr. Stervbo reported 
the highest level of trans-Res in wines: Pinot Noir, St. Laurent, Marzemino, Merlot, and 
Blaufrankisch with concentrations of 3.6 ± 2.9 mg/l (15.9 ±12.5 µM), 3.2 ± 1.8 mg/l 
(14.0 ± 8.1 µM), 3.0 ± 2.1 mg/l (13.1 ± 9.2 µM), 2.8 ± 2.6 mg/l (12.5 ± 11.5 µM), 2.6 ± 
1.3 mg/l (11.3 ± 5.5 µM), respectively [20]. Resveratrol is a natural phytoalexin, a 
defender of the plant in response to injury (trauma, UV light and infection by fungi). In 
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cooler climate (fungi infection) and zone of equator, high concentration of resveratrol is 
produced in grapes [21, 22, 23]. Besides Res sources from food or wines, supplements 
(125 – 1000 mg/capsule) of Res are also available on the market from different 
companies. 
1.2.3 Bioavailability and metabolism of resveratrol 
In recent years, a large number of researches reported the protective effect of 
resveratrol on cancer, heart disease, aging and Alzheimer’s disease [24, 25, 26, 33, 27]. 
However, higher dosage of Res (used in in-vitro studies) is hard to be reached in humans 
by dietary intake. In humans, resveratrol is highly absorbed, rapidly metabolized, mainly 
into sulfates and glucuronide–conjugates, by the stomach and liver, which are eliminated 
in urine.   
Resveratrol is metabolized in the intestine and then in the liver to sulphated and 
glucuronidated forms that are exported to target organs. With the development of the 
testing method on resveratrol metabolites, more metabolites can be detected from plasma, 
urine and feces. However, the quantity of metabolites differs from human objects. In 
early studies, trans-res glucuronides and sulfates (figure 1) were measured by using 
enzymatic method in which biding glucuronidase or arylsulfatase [28, 29, 30]. Recently, 
HPLC MS/MS improves the detection. Glucuronides and sulfates conjugates are the most 
frequently detected metabolites from plasma or urine, whereas other metabolites include 
dihydroresveratrol, disulfate, diglucuronides and glucuronide-sulfate [31, 32, 33]. 
Correspondingly, metabolites of 160 mg piceid administration are similar to 100 mg free 
resveratrol [31].  
Since resveratrol has high absorption rate but very low bioavailability, which 
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means that Res is also rapidly metabolized to conjugates in liver after consuming from 
mouth, resulting in low or no detectable level of resveratrol in plasma [34], whether res-
conjugates has any disease-protective effect like Res should be taken into consideration. 
In 2012, Carolina and Juan examined the three main metabolites of resveratrol, 
resveratrol-3-O-sulphate, resveratrol-3-O-glucuronide and resveratrol-4’-O-glucuronide, 
on the effect of cell growth inhibition, the cell cycle and apoptosis using human 
adenocarcinoma cell line (Caco-2 cell) cultures. Compared to pure resveratrol, they found 
that Res metabolites have similar antioxidant activity, inhibition on cell growth in a 
concentration-dependent manner with an increase in G0/G1 phase as well as the 
induction of apoptosis [35]. 
However, in 2011, Johnson et al., reported that piperine (derived from black 
pepper) can enhance the bioavailability of resveratrol in mice [36]. Twenty-four mice 
received a single dose of resveratrol (100 mg/kg via oral gavage) while the other 24 mice 
received combination resveratrol (100 mg/kg via oral gavage) plus piperine (10 mg/kg 
via oral gavage). Concentration of resveratrol and resveratrol-3-O-β-D-glucuronide were 
tested by LC/MS from blood samples with 8 time points from fifteen minutes to 2 days. 
And pharmacokinetic parameters were determined by area under the concentration-curve 
(AUC). The researchers found that the AUC was enhanced to 229% (from 5046 ng/mL h 
to 11584 ng/mL h) and the maximum serum concentration was increased to 1544% (peak 
from 2277 ng/mL to 35169 ng/mL at 0.25 h) with the addition of piperine [36]. This 
research is meaningful for the application of dietary resveratrol in future human clinical 
trail that blood concentration of Res can reach the pharmacological effect from the study 
in vivo.  
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1.2.4 Toxicity  
With short period time of oral resveratrol intake, animal and human studies 
showed Res appeared to be well tolerated without side effects, except for the dose of 4 g 
and 2.5 or 5 g per day for two human studies [37,38]. In 2010, Dr. Le Porte reported a 
study [37] based on eight healthy human subjects who were given 2 g Res twice per day, 
that they had uncomfortable symptoms including mild episodic diarrhea/loose stool, rash 
and headache at the beginning of the treatment. From Dr. Elliott’s study [38] on healthy 
volunteers with treatment of 2.5 or 5 g Res daily for 28 days, the report indicated, 
“Adverse events were generally mild in nature and reversible”. These two human studies 
implicate that high doses of Res (2.5 g and above daily) may induce mild side effects in 
some of healthy subjects at the beginning and these side effect symptoms may become 
less severe after a period of time. Indeed, such hypothesis still needs more evidence to 
support that it is true. From one rat study [39], the safe or toxic levels were evaluated. 
Both male and female rats were gavaged with 0, 300, 1000, and 3000 mg trans-Res/kg 
body weight (BW)/day for 28 days. Most of the adverse events occurred in the rats 
administered 3000 mg/kg BW/day. Two male rats were found dead in the 3000 mg/kg 
BW/day group. The toxic effects of reduced body weight increased clinical toxicity, renal 
lesions, and increased incidence of severe nephropathy were observed in the 3000 mg/kg 
BW/day group [39]. From human studies, there is no valid strong evidence indicating 
long-term effect of toxicity in taking resveratrol, so further study should be performed. 
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1.2.5 French paradox 
French paradox is the low prevalence of coronary heart disease (CHD) associated 
with high intake of dietary cholesterol and saturated fat [40], which is opposite from what 
we have heard “high-fat diet increases CHD rate”. An epidemiological study on coronary 
heart disease (CHD) mortality in European reported very low CHD mortality in the 
regions of Lille (northern France), Strasbourg (south western France) and Toulouse 
(south western France), as compared with other European regions [41].  The WHO 
dietary recommendation for saturated fat is less than 10% of total energy, but French 
people consume 15% energy from saturated fat. Thus, they should be exposed to high 
risk of CHD but they are not [42].  
Scientists then worked hard to elucidate the French paradox. Several hypotheses 
had been proposed and debates began to focus on alcohol consumption especially red 
wine, which is the common identifiable element. A European study [43] reported that the 
wine consumption could decrease 24-31% for all causes of mortality. The dominant 
theory is that the polyphenols can have anti-oxidative function on LDL and thus prevent 
atherogenesis and heart disease [44]. In vitro, 3.8 or 10 µmol/L of polyphenols derived 
from red wine inhibited LDL peroxidation by 60 and 98%, respectively [45].  Also, mild-
to-moderate wine drinking habit can reduce platelet and monocyte adhesion, a variety of 
cancers, and Alzheimer diseases.  
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1.3 Hypothesis and objectives: 
To date, there has been little research investigating the effect of resveratrol, with 
consumption attainable concentrations, on the inflammation effect on human cells. In our 
study, we tested the hypothesis that whether resveratrol, at dietary and pharmacological 
concentrations, is safe for the dosage? Has anti-inflammation effect in our cell lines? And 
has any structure specificity?   
We chose two human immune related cell models, human THP-1 monocytes, and 
PMA differentiated human THP-1 macrophages to address our objectives as below: 
1. Is the dosage from dietary to pharmacological level of Res safe for THP-1 or P-
THP-1 cells? If not, how toxic is it? 
2. By testing cell cycle and cell proliferation related genes on THP-1 monocytes 
treated with Res, how does Res regulate cell proliferation and exert cancer prevention 
effect on THP-1 monocytes? 
3. How does Res modify pro-inflammatory cytokines in THP-1 and P-THP-1 cells? 
Does it exert induction or inhibition effect on inflammation? 






Chapter 2 Effect of resveratrol in THP-1 
2.1 Introduction: 
2.1.1 Resveratrol 
Resveratrol (3, 5, 4’ –trihydroxy-trans-stilbene) is a phytoalexin found in a 
variety of foods (e.g., grapes, peanuts, red wine, and berries).  Resveratrol (Res) level is 
elevated in response to environmental stress, injury, UV irradiation, and fungal infection. 
Res has been shown to exert anti-oxidant, anti-cancer and anti-inflammatory effects [15, 
16, 17]. Res is also known as 3, 4’, 5-stilbenetriol in cis and trans isometric forms (trans-
isoform is more widely investigated). 
2.1.2 Cancer prevention by resveratrol 
The CDC website [46] presented the number of deaths from 10 leading causes in 
the United States during 2010, according to the National Vital Statistics System. In 2010, 
a total of 2,468,435 deaths occurred in the United States. The first two leading causes of 
death, heart diseases (597,689 deaths) and cancer (574,743), accounted for nearly 50% of 
all deaths. Around 30 – 40 % of cancer is directly linked to the diet we eat.  Right now, 
besides genetic risk of cancer, with more incidences of environment pollution, radiation 
exposure, stress and imbalance hormones, chronic inflammation, unhealthy diet and 
physical inactivity, UV light, and other carcinogens, people have higher chance to 
develop cancer [47]. Cancer development starts with initiation, and then goes through 
promotion, progression and metastasis. Among the four stages of cancer development, 
only stage I refers to benign tumor, whereas stage II – IV belong to malignant cancer. 
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Here what we talk about cancer is from stage II – IV, not including benign tumor. In 
stage I, a benign tumor, non-cancerous, has a slower growth rate than malignant tumor, 
which is surrounded by an outer cover (fibrous sheath of connective tissue) or remains 
with the epithelium to maintain cohesive and remain well differentiated. On the other 
hand, malignant neoplasm has such type of irregular shape, rapid growth, not 
encapsulated, infiltrating/metastasis ability, difficulty to be removed, tend to recur after 
removal and life-treating [48, 49].  
Cell cycle is a highly ordered process with one-direction when cells duplicate. 
When cells undergo the process of cell cycle, they need to transit through G1, S, G2 and 
M phases with two kinds of circuits-intrinsic mechanisms (act in each cell cycle to order 
events) and extrinsic mechanisms (act when a defect is detected) [50].  Normal regulation 
of cell cycle for cell proliferation is essential in eukaryotic cells, which is especially 
important for humans to maintain normal cells growing because any uncontrolled cell 
proliferation under unregulated cell cycle leads to cancer eventually. Thus, cell cycle 
regulation is like a protective umbrella to inhibit abnormal cell proliferation. Generally, 
when a cell needs to proliferate, it enters in G1 phase first, and then S, G2 and M phase to 
complete this process. If the DNA is damaged or mutated or the process is not properly 
going well, checkpoints (molecular surveillance system) from each phase have to stop the 
process, which is called “arrest”.  G1 checkpoint, also called R-point (restriction point), is 
the first checkpoint, which is located at the end of G1 phase. In G1 cells, cells need to 
grow cell size, double organelles and synthesize proteins. If cells pass the G1 checkpoint, 
they then move to S phase. If DNA is damaged, cells are either arrested in G1 phase 
before entering into S phase, or retreat back into resting state - G0 phase. This checkpoint 
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is critical for the cell in making a right decision in the cell cycle. Thus, R point is a very 
important molecular target for cancer prevention and therapy. After finishing DNA 
synthesis and chromosome duplication in S phase, cells enter G2 phase, where cell 
prepares for mitosis. G2/M check point is located at the end of G2 phase, which monitors 
whether cells are normal or not to begin mitosis, and also to provide an opportunity to 
stall the proliferation or repair of DNA damaged cells. The last checkpoint is called 
spindle checkpoint located in M phase to maintain that all the chromosomes should align 
at the mitotic plate and be under bipolar tension [51, 52]. If mutations happen on critical 
genes of these checkpoints, then abnormal cells will be allow to proliferate without 
control and develop cancer finally.  
In recent years, Res was found to be a good candidate for chemotherapy and 
chemoprevention, by exerting an inhibition on cancer cell proliferation and induction of 
apoptosis. Res is involved in intracellular signaling pathway to keep homeostasis of cell 
growth and differentiation, which includes various cyclins, cyclin-dependent kinases 
(CDk), CDk inhibitors, and checkpoint kinases (Chk) [53]. From the study of cells in 
culture, tissue and xenografted animals treated with Res, Res was found to targeted 
several different signals by either down regulating cyclin-CDks and/or up regulating CDk 
inhibitors on inhibition of cell proliferation [54]. By treating promyelocitic cell line HL-
60 with Res, Fulvioet al. (1998) found that a complete arrest of proliferation in the S 
phase by at least 30 µM Res [55]. Similarly, in human histiocytic lymphoma U937 cell 
lines, Res was found to induce arrest in the S phase at low concentration (30-60 µM), 
whereas higher concentration didn’t have same S phase arrest [56]. Both reports showed 
increase in cyclin A and E, and the cell cycle arrest reversible [55, 56].  
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On the anti-leukemia effect of resveratrol, Res exerts growth inhibition, induces 
apoptosis and blocks in S phase progression by being mostly dependent on the 
concentration of Res [57]. In 2002, Andrew et al., reported that apoptosis with IC50 
values of 70-150 µM in five human cancer cell lines (MCF7, SW480, HCE7, Seg-1 and 
HL60) [58]. Similarly, Helene et al., (2002) reported that apoptosis was induced in their 
Res treated lymphoid and myeloid leukemia cells with IC50 5-43 µM [59]. From several 
different studies on THP-1 cells, CEM-C7H2 and Jurkart cells treated by Res, the Res-
induced apoptosis was showed to be independent of Fas/FasL pathway [60, 61]. In 
contrast, apoptosis was undetected in Res treated HL60 cells [62, 63]. Furthermore, Res 
can induce mitochondrial release of cytochrome c in THP-1 cells followed by the 
activation of caspase-9 and downstream caspases [60]. Such evidence suggests that Res 
can induce apoptosis through Fas/FasL –independent pathway on specific leukemia cell 
types, whereas Res induces apoptosis in THP-1 cells through the mitochondrial pathway. 
2.1.3 Hypothesis: 
THP-1 monocytes resemble human monocytes in many biological properties, like 
morphological aspect and cytokine secretion. Also THP-1 is a p53 mutant cancer cell line, 
and is a good model to study the effect of Res on cancer prevention. In our study, we 
investigated the effect of Res (0-25 µM) in THP-1 cells to test its toxicity on cell viability, 
cell cycle, cell proliferation related genes expression and pro-inflammatory cytokines 
productions from THP-1 monocytes with or without LPS or PAM stimulation.  
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2.2 Materials and methods: 
2.2.1 Material and reagents: 
Cell culture media, DMEM (Cat #11,995) and RPMI 1,640 (Cat #11,875), were 
purchased from GIBCO (Grand Island, NY, USA). Lipopolysaccharides from 
Escherichia coli 0111:B4, resveratrol (Res), pterolstilbene (Ptes), genistein (Gen) were 
obtained from Sigma-Aldrich (St. Louis, MO, USA). Strata Script First Strand 
Complementary DNA Synthesis kit was purchased from Stratagene (Santa Clara, CA, 
USA). TaqMan Universal PCR Master Mix for Real-time PCR was obtained from 




Table 2. Material information 
Name Company Address 
Cell culture media, DMEM (Cat 
#11,995) 
RPMI 1,640 (Cat #11,875) 
GIBCO Grand Island, NY, USA 





Phorbol 12-myristate 13-acetate 
(PMA) 
Sigma-Aldrich St. Louis, MO, USA 
Pam3CSK4 InvivoGen San Diego, CA, USA 
AffinityScript Multi Temperature 
cDNA Synthesis Kit 
Agilent 
Technologies 
Santa Clara CA , USA 
TaqMan Universal PCR Master Mix 
for Real-time PCR 









CYP1B1 (Hs02382916_s1 ) 
P21-CDKN1A (Hs00355782_m1) 
P27-CDKN1B (Hs01597588_m1) 
GAPDH (Hs02758991_g1 ) 
Applied 
Biosystems 
Carlsbad, CA, USA 









2.2.2 Cells and cell growth conditions: 
THP-1 cells: 
Human THP-1 cells were obtained from American Type Culture Collection 
(ATCC, Manassas, VA, USA) and were cultured in RPMI 1,640 media, which contained 
10% fetal bovine serum (FBS) and 1% amphotericin B/streptomycin/penicillin, 
hereinafter referred as the complete medium (CM). Cells were incubated at 37 °C in 
humidified air with 5% CO2 in ambient air. Prior to experiments, THP-1 cells were grown 
in the medium for 24 hours for adaption. After 24 h, the medium was removed and 
replaced by fresh CM with different concentrations of resveratrol. 
2.2.3 Evaluation of cell viability by Trypan Blue staining in THP-1 cells 
THP-1 monocytes (1×105 cells/mL, 2mL) were plated in 6-well plates (Costar; 
Corning Incorporated, Corning, NY, USA) for 24 hours and then treated with (1, 5, 10, 
25 µM) or without resveratol (control, DMSO) for 0, 24, 48 hours. Total cell count for 
each sample was measured with Trypan Blue staining. 
2.2.4 Cell cycle analysis/FACS analysis 
THP-1 monocytes (1×105 cells/mL, 10mL) were plated in 75-cm2 flasks overnight 
and then treated with (1, 5, 10, 25 µM) or without resveratrol (control, DMSO) for 48 
hours. Cells were washed with PBS three times in 50-mL polypropylene tubes (BD 
Biosciences, Bedford, MA, USA), and then fixed in 15 mL 70% chilled ethanol overnight 
at 4 °C.  
DNA content of the cells was determined by flow cytometry using a FACScalibur 
cytometer (Becton Dickinson, San Jose, CA). Washed cells were fixed in ethanol and 
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stained for DNA content using propidium iodide. Flow cytometric data files were 
collected and analyzed by using the CELLQuest program (Becton Dickinson). A total of 
10,000 cell events were collected for DNA analyses. Cell cycle distribution percentages 
of stained nuclei were calculated using Modfit LT software (version 3.0, Verity Software 
House, Inc., Topsham, ME). Calibration standards (LinearFlow Green and DNA QC 
Particle Kit) for verification of instrument performance were purchased from Molecular 
Probes (Eugene, OR) and Becton Dickinson, respectively [64, 65]. 
2.2.5 Total RNA isolation, cDNA synthesis, and gene expression analysis 
using real-time PCR  
To determine the mRNA expression level in THP-1, such mRNA expression was 
measured by real-time PCR. THP-1 cells were cultured in 6-well plates, treated with 
control (DMSO), or resveratrol (1, 5, 10, 25 µM) for 48 hours. Thereafter, LPS (10 
ng/mL) or Pam3CSK4 (500 ng/mL) were added for another 2 hours. Cells were harvested 
and washed with PBS three times and then total RNA were isolated following TRIzol 
protocol (Life Technologies, Grand Island, NY, USA). In brief, cells were broken in 1 
mL TRIzol for 5 minutes. The aqueous phase, containing mRNA, was collected by 
centrifuging step, after 200 µL chloroform were added in each EP tube.  Isopropanol was 
added for precipitating total RNA overnight at 4 °C. RNA was washed with 75% ethanol 
twice, and then a 0.2 µg/µL RNA solution was prepared. 
One µg of total RNA was used to reverse transcribe cDNA by using 
AffinityScript Multi Temperature cDNA Synthesis Kit (Agilent Technologies, Santa 
Clara, CA, USA). Real-time PCR amplification of mRNA levels was performed in the 
ABI Prism 7900HT Sequence Detection System by using TaqMan universal PCR Master 
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Mix (Life Technologies, Grand Island, NY, USA) according to manufacturer’s protocol. 
Five µL of cDNA were used for real-time PCR. The TaqMan gene expression assay was 
used to detect IL-1β, IL-6, IL-8, COX-2, MCP-1, TNF-α, P21 and P27. The mRNA 
levels were normalized to an internal control, GAPDH mRNA.    
2.2.6 p21 protein determination by using flow cytometry 
THP-1 Cells were re-suspended in 300 mL of RPMI medium. Formaldehyde 
(16%) was added to give a final volume of 1.5% and cells were fixed for 15 min at room 
temperature followed by centrifugation. Pellets were re-suspended by vortexing in 50 mL 
RPMI media. Tubes were chilled and then 1 mL of ice-cold methanol was added while 
again vortexing to prevent cell clumping. Samples were capped tightly and stored at -
20 °C until analysis by flow cytometry [66,67].  
2.2.7 Statistics: 
Data were analyzed with GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, 
CA, USA) and are presented as means ± SE. A one-way ANOVA followed by post hoc 
analysis. The Tukey test was used to determine the statistical significance among 






2.3.1 Effect of resveratrol on the growth of THP-1 monocytes  
The highest growth rate of THP-1 monocytes was observed with the DMSO 
controls.  A similar growth rate was observed with the resveratrol (Res) 1 µM treated 
cells. A dose dependent inhibition of THP-1 monocyte growth was seen with higher 
doses of resveratrol (Figure 2A). Treatment with Res 25 µM was associated with minimal 
cell growth at 24 hours and cell death at 48 hours. Cells treated with Res 10 and 25 µM 
had a 36.5% and 69.04%, respectively, reduction in growth compared to controls at 48 
hours. Res 25 µM was associated with a loss of 44.5% of cells from the initial plating. 
The half maximal inhibitory concentration (IC50) of Res for THP-1 cells was 17 µM 






Figure 2. Effect of resveratrol on the cell growth and IC50 in THP-1 monocytes and P-THP-
1 macrophages. THP-1 monocytes (1×105/mL) were plated in 6-well plates treated with (1, 5, 10, 
25 µM) or without resveratrol (control, DMSO) for 48 hours. Total cell count of THP-1 cells was 
measured using Trypan Blue staining after 24 and 48 hours (Fig. 2A). Fig. 2 (B) showed the half 
maximal inhibitory concentration (IC50) of resveratrol for THP-1 and P-THP-1, respectively. 























































2.3.2 THP-1 cell cycle analysis and inducement of apoptosis by 
resveratrol 
Cell cycle analysis was performed to examine the influence of Res (1, 5, 10, 
25µM) on the progression of THP-1 cells through the cell cycle (Figure 3). Res 1 µM did 
not have any effect on cell cycle progression, compared to control. Res 5 and 10 µM 
caused a 1.2- and 2.0-fold increase, respectively, in % cells in S phase, compared to 
control. This suggests that there was a block or depressed progression through the S 
phase. In contrast, Res 25 µM increased the % cells in G0/G1 phase by 57.9%, indicating 
arrest in this phase. A 17-fold increase in sub G0/G1 was seen with res 25 µM, indicating 
significant apoptosis at this high dosage. 
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Effect of resveratrol on the cell cycle progression of THP-1 monocytes 
                              
        Control (DMSO)                  Res 1 µM   Res 5 µM  
 
Res 10 µM  	   Res 25 µM	  
 
Fig. 3A 

















Figure 3. Effect of resveratrol on cell cycle progression of THP-1 monocytes. THP-1 
monocytes (1×105/mL) were plated in 75-cm2 flasks for 24 hours and then treated with (1, 5, 10, 
25 µM) or without resveratrol (control, DMSO) for 48 hours. (A) Cell cycle progression was 
examined using flow cytometry. (B) Cell cycle distribution of collected cells was determined by 
using flow cytometry. Apo, apoptosis=Sub G0/G1. Percentage of cells in each phase of the cell 
cycle (sub G0/G1, G0/G1, S, and G2/M) was calculated using CELL Quest. Values were 
expressed as the mean ± SE of 6 separate experiments. * was used to indicate significantly 






































2.3.3 Effect of resveratrol on cell proliferation gene expression in THP-1 
monocytes 
p21 and p27 are genes related to cellular proliferation. The mRNA level of these 
genes was determined to examine the mechanism of Res inhibition of expression of these 
genes in THP-1 cells. Cell cycle analysis indicated that high concentration of Res at 25 
µM induced apoptosis in THP-1 cells. Res, starting at 5 µM, also inhibited growth of 
THP-1 cells.  
Increases of 7.2-fold and 25.8-fold in p21 mRNA expression were found in THP-
1 cells treated with Res 10 and 25 µM, respectively (Figure 3A left). The expression of 
p21 protein (Figure 3B) was increased as Res treatment dose increased. Increased 
expression was first detected with Res 5 µM (3.1-fold). This expression was increased to 
3.6- and 4.1-fold, respectively, using Res 10 and 25 µM. Res had no effect on p27 mRNA 
expression in THP-1 cells (Figure 3A right). Together, these findings suggest Res may 















Figure 4. Regulation of cell proliferation related gene expression in THP-1 monocytes 
treated with resveratrol. THP-1 monocytes were grown for 24 hours and then treated with (1, 5, 
10, 25 µM) or without resveratrol (control, DMSO) for 48 hours. p21 and p27 mRNA expression 
(A) was measured by using quantitative RT-PCR. Values were expressed as mean ± SE of 3 
separate experiments. Percentage of cells expressing p21 protein (B) was measured by using flow 
cytometry, according to manufacturer’s recommendations. Means with different letters were 
significantly different (p<0.05). p21: cyclin-dependent kinase inhibitor 1A (CDKN1A). p27: 




















































































2.2.4 Effect of resveratrol on pro-inflammatory cytokine expression in 
THP-1 cells after LPS or PAM stimulation 
Exposure of THP-1 cells to a dosage of Res (1, 5, 10 µM), attainable by dietary 
intake, may have a different effect on cellular marker expression than a pharmaceutical 
dose (25µM).  The expression of pro-inflammatory cytokines was determined to address 
this question. Cells were treated with the inflammatory stimulants LPS and PAM. DMSO 
treatment served as a control. THP-1 cells had increased marker expression only at the 
pharmaceutical dose of 25 µM resveratrol (Figure 4C).  
IL-1β- IL-6, IL-8, MCP-1, COX-2 and TNF-α mRNA expressions were all 
enhanced significantly compared to control after LPS and PAM stimulation (Figures 4A 
and 6B). No change in expression was seen in LPS stimulated cells with Res 1 µM. A 
dose dependent increase in expression of IL-1β expression was seen with Res 5 to 25 µM. 
A similar increase in IL-6 was seen with Res 10 and 25 µM. No increase in MCP-1 or 
COX-2 expression was seen until a dose of Res 25 µM was reached. 
No change in THP-1 expression was observed using dietary doses of Res and 
stimulation with PAM.  Increased mRNA expression of IL-1β (2.3-fold), IL-6 (3.8-fold), 




Effect of resveratrol on pro-inflammatory cytokine mRNA expression in THP-1 
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Effect of resveratrol on pro-inflammatory cytokine mRNA expression in THP-1 
monocytes after stimulation with PAM 
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Effect of resveratrol on pro-inflammatory cytokine mRNA expression in THP-1 
monocytes without stimulation 



































































































































































Figure 5. Effect of resveratrol on pro-inflammatory cytokine expression in THP-1 
monocytes after LPS or PAM stimulation. THP-1 monocytes (2.5×105/mL) were cultured for 
24 hours and then treated with (1, 5, 10, 25 µM) or without resveratrol (control, DMSO) for 48 
hours. (A) 10 ng/mL LPS were added to each well and incubated at 37 °C for 2 hours. (B) 500 
ng/mL PAM were added to each well and incubated at 37 °C for 2 hours. (C) Cells were 
incubated at 37 °C for an additional 2 hours only with resveratrol and DMSO treatment. Cytokine 
mRNA expression was measured by using quantitative RT-PCR. Values were presented as mean 
± SE of 3 separate experiments. Means with different letters were significantly different (p<0.05). 





Resveratrol is currently sold in the market as supplements and advertised to exert 
anti-cancer, anti-oxidant and anti-inflammation functions, which were observed in 
numerous in vitro studies. However, the effect of Res at concentrations attainable by 
dietary intake is lacking from published in vitro studies. Thus, this study was designed to 
establish how Res treatment duration and concentrations, attainable by dietary intake, 
might impact on its anti-inflammation function. THP-1 monocytes, derived from a 
leukemia cell line, were chosen to use in our study, because not only for the economic 
reason, but also mainly because the effects on both cancer and inflammation can be 
studied in the present research.  
In our study, the influence of Res on THP-1 cell proliferation, cell cycle and 
apoptosis, pro-inflammatory cytokines and mediators’ gene expression was examined to 
determine its effect related to cancer prevention and chronic inflammation. In chapter 3, 
the specificity of Res on cell type and on its stilbene structure will be further discussed. 
Firstly, we examined the influence of Res concentration, ranging from dosages 
attainable by diet to therapeutic level, on THP-1cells. The half maximal inhibitory 
concentration (IC50) is a measure of the effectiveness of a substance in inhibiting a 
specific biological or biochemical function. Our results showed that IC50 for THP-1 
monocytes treated with Res was 17 µM, indicating that Res at 17 µM caused half of the 
cells death. Res is considered to be toxic for human monocytes because of its low 
concentration to reach IC50.  
From cell cycle results on THP-1 cells, Res induced anti-proliferation effect on 
cell growth with different cell cycle phase arrest in a dose-dependent manner. The effects 
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of Res on cell cycle are clearly variable depending on the concentration of Res. At lower 
dosages, Res (5 and 10 µM) just induced S-phase arrest for inhibiting the proliferation of 
THP-1 without apoptosis. However, Res at 25 µM appeared to be toxic, and induced 
G0/G1 phase arrest and apoptosis in THP-1 monocytes.  
Other indicators, p21 and p27, also showed partial and/or alternate mechanism on 
how Res regulates cell proliferation in THP-1 monocytes. p21 / WAF1 is also known 
as cyclin-dependent kinase inhibitor 1 or CDK-interacting protein 1, which in humans is 
encoded by the CDKN1A gene. The p21 protein binds to and inhibits the activity 
of cyclin-CDK2 or -CDK1 complexes, and thus functions as the p53-dependent (tumor 
suppressor gene) regulator of cell cycle progression at G1. On the other hand, the p21 
protein can also interact with proliferating cell nuclear antigen (PCNA), a DNA 
polymerase accessory factor, and plays a regulatory role in S phase DNA replication and 
DNA damage repair. In our study, Res gradually increased p21 mRNA (starting from 10 
µM) and protein expression (starting from 5 µM), whereas p27 mRNA expression was 
not influenced by Res treatment. Makoto Akashi et al., [68] reported that THP-1 is p53-
deficient leukemia cell line. The transcription of p21 is directly regulated by p53 [69], 
and if p53 is mutated, such cells cannot induce p21 expression due to p53 mutation. 
However, in 1994, Michieli et al., demonstrated that p21 is capable of inducing a  p53-
independent pathway [69]. Thus, the induction of p21 by Res in THP-1 cells, together 
with cell cycle data, supported that the Res induced p53-independent p21 gene expression 
may be responsible for blocking cell-proliferation and inducing S phase arrest (Res 5 and 
10 µM) or G0/G1 arrest (Res 25 µM) depending on Res concentration. Res is also 
suggested to be a potential candidate for the treatment of p53-mutant and multidrug-
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resistant leukemia cells, but not the main chemotherapeutic agent due to its low IC50 on 
certain cells.  
For the effect of Res on pro-inflammatory cytokines and mediators in THP-1 
monocytes, we will further discuss later in chapter 3 discussions together with results 




Though resveratrol has been studied for more than two decades, its effects on 
innate immune cells under physiologic attainable conditions are seldom examined. In our 
study, the first aim is to determine the effect of Res in THP-1 monocytes regarding the 
toxicity and cancer prevention function. Results from the present study showed that Res 
exerted anti-proliferation on THP-1 cells, induced apoptosis on THP-1 cells with 
pharmaceutical concentration, as well as anti-cancer function by elevating p21 gene 
expression, together with S-phase arrest and G0/G1-arrest in cell cycle with dietary and 
pharmaceutical concentrations, respectively. Our conclusion is that resveratrol exhibited 
concentration-dependent toxicity, induced different cell cycle arrest in a concentration 
manner, and exhibited blocking of cancer development through the induction of p53-
independent p21 gene expression in human THP-1 monocytes.  
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Chapter 3 Res exerts cell type or inherent stilbene 
structure specificity in the regulation of inflammation 
mediators 
3.1 Introduction: 
3.1.1 Monocytes and macrophages 
Monocytes and macrophages are part of the immune system. Monocytes circulate 
through the bloodstream for one to three days, and then travel into specific tissues to 
differentiate into resident macrophages or dendritic cells (specifically to replenish 
macrophages or dendritic cells) by receiving the inflammation signals [13]. Monocytes 
can move quickly (8-12 hours) to sites of infection in the tissues and differentiate into 
macrophages and dendritic cells to elicit an immune response. 
Both macrophages and monocytes function in innate immunity defense. Besides 
protecting our body as first barrier from non-specific infection, macrophages can also 
help to initiate specific defense mechanisms (adaptive immunity) in mammals [70]. 
Several cell types (macrophages, neutrophils, dendritic cells and B cells) in the immune 
system engulf microorganisms via phagocytosis. To aid in the destruction of 
microorganisms, several important factors are release within phagolysosome: phagocyte 
oxidase, nitric oxide, anti-microbial proteins, anti-microbial peptides, binding proteins 
and hydrogen ion transport [70]. 
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3.1.2 Chronic inflammation and cancer: 
Inflammation is a sword with two edges. Acute inflammation is the defense of 
infections, however, on the other side, chronic inflammation showed a link with one 
fourth of cancer incidence by failing in the precise immune regulations and cellular 
homeostasis. Previous research established that the mediators from the inflammation 
response could cause both genetic and epigenetic changes (mutations on p53, DNA 
methylation and post-translational modifications) and lead to uncontrolled development 
and progression of cancer. Through inflammation, mediators are secreted to induce 
numerous cascade-signaling pathways, including reactive oxygen and nitrogen species, 
cytokines, prostaglandins and growth factors. Substantial evidence [71, 72] indicated that 
inflammation mediators can promote cancer development.  
In activated inflammatory cells, the enhanced production of reactive oxygen and 
nitrogen species (e.g., OH!, NO!, O2!, OONO!) can further induce lipid peroxidation, 
reactive aldehydes-malondialdehydes (MDA) and 4-hydroxynonenal (4-HNE). Both 
MDA and 4-HNE are potential cancer inducers capable of point-mutating tumor 
suppressor genes [73]. Interestingly, NO! can both activate p53 tumor suppressor 
pathway and induce oncogenic mutations on p53 gene in a concentration-dependent 
manner [74]. With low concentration, NO!  can induce p53 post-translational 
modification through ATM and ATR signaling pathways to accumulate p53, which can 
inhibit cell growth and induce apoptosis. However, mutated p53 accumulates as a result 
of this action. On the other hand, a higher amount of NO! helped to develop lymphoma 
and sarcomas in p53-deficient mice. NOS2 (nitric oxide synthase 2) expressed high 
amount of NO! for a longer time whereas NOS1 and NOS3 just produce low level of 
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NO!  [75]. Mutation of p53 was found to increase in those patients who had colon 
inflammation [76].   
There are two kinds of cytokines: pro- inflammatory (maintain- inflammation and 
anti-inflammatory (reduce inflammation and promote healing) ones, which can further 
induce or inhibit tumor development [77]. Under normal situation, cytokines are initiated 
and terminated under real attack (e.g., bacteria, virus, infection, trauma). However, 
uncontrolled and sustained production of cytokines can lead to chronic inflammation 
rather than acute inflammation, and alter cell functions and cell type. Pro-inflammatory 
cytokines include IL-1, IL-6, IL-8, TNF-α, CSF and MIF (table 1), which increase 
vascular adhesion molecules, vascular endothelial growth factor-VEGF and other growth 
factors and then contribute to angiogenesis and metastasis in cancer progression [78]. 
Carcinogens are found in foods, cigars, and industrial pollutions, which are reported to 
increase most of the pro-inflammatory cytokines and chemokines [79]. One good 
example is chronic infection of Helicobacter pylori and gastric carcinoma. Helicobacter 
pylori (H. pylori) are micro-aerophilic spiral-shaped Gram-negative bacteria, which in the 
stomach. H. pylori infection affects 50% of the population all over the world [80]. 
Specially, there are much more incidence of stomach cancer in some part of Asia [81]. 
One Korean study on Asian population also reported an increased risk of gastric cancer, 
which was associated with an elevated IL-1β expression in H. pylori-infected patients 
[82]. Furthermore, many reports showed that elevated expression of IL-8, IL-6, CSF, 
MIF and TNF-α are associated with tumor development [83, 84, 85]. IL-8, originally 
named as monocyte-derived neutrophil chemotactic factor (MNDCF), can act as 
autocrine growth factor to help angiogenic activities in several cancer types [86, 87]. IL-6 
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can induce anti-apoptotic genes Bcl2 and Bcl-XL to suppress anti-cancer function by 
mediating pRb hyperposphorylation [88, 89]. MIF has a strong association with cancer by 
regulating p53 suppressor genes, cell cycle and senescence. In addition, MIF is also 
involved in increasing COX-2 and NOS2, inhibiting apoptosis and activating NF- κB 
[90].  NF-κB is an important transcription factor that induce cancer during chronic 
inflammation, whose role is to inhibit apoptosis and rather than to elevate cell 
progression, angiogenesis and metastasis [91,92]. Furthermore, COX-2, stimulated only 
by inflammation, hypoxia and Wnt-signaling [93], has been reported to promote cancer in 
epithelial cell and stroma by elevating Bcl2 expression and members of matrix 
metalloproteinase family [94].  
3.1.3 Inflammation and vascular disease: 
Lots of evidence from cohort studies support the correlation between chronic 
inflammation and cardiovascular risk, that the inflammatory parameters (fibrinogen, C 
reactive protein, and serum amyloid A), as well as cellular adhesion molecules and 
cytokines, are all associated with increased risk of vascular and heart disease. From Dr. 
P .M. Ridker’s review [95], he mainly reviewed the relationship between C reactive 
protein (CRP) and epidemiology of coronary risk. In response to acute inflammation, 
infection and stimuli, the liver secrets IL-6 and elevates CRP rapid responses in the blood. 
However, with the loss of homeostasis of pro-inflammatory cytokines, CRP may lead 
directly to chronic inflammation and future coronary events. High-sensitivity assays for 
CRP (hs-CRP) are used to evaluation the extent of chronic vascular inflammation. An 8-
year cohort study, which involved 22,000 healthy men, found that those in the highest 
quartile of hs-CRP compared to those with lower level of hs-CRP, have two-fold 
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elevation in stroke, three-fold increase in the risk of myocardial infarction, and a four-
fold enhancement in developing peripheral vascular disease. Further, similar results were 
also reported in elder people and women [96, 97]. 
On the other hand, available evidence indicated that active cytokines secretion 
resulted in endothelial cell injury and initiation of arterial-wall inflammatory processes. 
There is another link between periodontal disease and inflammation. Periodontal disease 
is initiated by bacterial attack orally around the gum, which leads to release of pro-
inflammatory cytokines (IL-1, IL-6 and TNF-α). Thus, such action shares an association 
between periodontal disease and coronary disease [98].  
3.1.4 Anti-inflammation effect of Res 
Recently, studies [99] revealed that resveratrol exerted anti-inflammation function 
by inducing antioxidant activity, blocking NF-κB signaling pathway and other pro-
inflammatory mediators (figure 6). Firstly, Res exerts anti-oxidant property by reducing 
hydrogen peroxide-induced cytotoxicity and intracellular accumulation of ROS [100, 101, 
102]. In chronic inflammation, macrophages remain activated and continue to release 
pro-inflammatory signals to induce further trauma, DNA mutant and other chronic 
disease including cardiovascular disease, type II diabetes, brain damage and cancer. TNF-
α is a potential target for triggering other pro-inflammatory cytokines (IL-1, IL-6, IL-8, 
granulocyte macrophage-colony stimulating factor-GM-CSF). In 2009, Res was found to 
inhibit LPS-induced TNF-α, IL-1β, IL-6 expression in mouse monocytes [103]. In 
angiotensin II induced adhesion of leukocytes, Res reduced cellular adhesion molecule 
expression, monocyte chemotactic protein-1 (MCP-1) and macrophage inflammatory 
protein-1-alpha (MIP-1α) [104]. Kang et al. and Olholm et al. presented further 
 46 
confirmation of inhibition on such cytokines, TNF-α and IL-6, that both were decreased 
in either LPS-induced RAW264.7 mouse macrophages by Res (0.1-10 µM) [110] or in 
human adipose tissue explants [105]. 
COX-2, named cyclooxygenase-2 or prostaglandin-endoperoxide synthase2 
(PTGS2), is an enzyme that induces prostanoids expression and inflammation. 
Physiological symptoms are fever and pain. Researchers found that increased COX-2 was 
associated with inflammation and certain cancers [106, 107, 108]. In 1998, Subbaramaiah 
et al., demonstrated that Res inhibited prostaglandin E2-PGE2 by inhibiting COX-2 
expression [109]. Recently, Kang et al., (2009) reported that resveratrol significantly 
inhibited the PMA plus A23187-induced TNF-α, IL-6 and IL-8, as well as COX-2 
expression in mast cells (HMC-1) [110]. 
 
Figure 6. Anti-inflammatory function of Resveratrol in several different signal pathways. 
iNOS (inducible NO synthesis), IL (interleukin), TNF-α (tumor necrosis factor-α), MCP-1 




In chapter 2, we have tested the effect of Res in THP-1 monocytes related cell 
viability and cancer prevention by induced p21 elevation and cell cycle arrest. In chapter 
3, we further examined the specificity of Res on either cell type or its stilbene structure. 
In our study, we compared the cell viability from THP-1 monocytes and P-THP-1 
macrophages, and the pro-inflammatory cytokines productions in both cell lines induced 
by LPS or PAM inflammation. Furthermore, to figure out why Res has such effects at the 
molecular level, we compared it with two other bioactive compounds, one shared the 
same stilbene structure, and another one possessed no stilbene structure, in both THP-1 





3.2 Materials and methods: 
3.2.1 Materials and reagents: 
Cell culture media, DMEM (Cat #11,995) and RPMI 1,640 (Cat #11,875), were 
purchased from GIBCO (Grand Island, NY, USA). Lipopolysaccharides (derived from 
Escherichia coli 0111:B4), resveratrol (Res), pterolstilbene (Ptes), genistein (Gen) were 
obtained from Sigma-Aldrich (St. Louis, MO, USA). Strata Script First Strand 
Complementary DNA Synthesis kit was obtained from Stratagene (Santa Clara, CA, 
USA). TaqMan Universal PCR Master Mix for Real-time PCR was purchased from 
Applied Biosystems (Carlsbad, CA, USA). More material information can be found in 
table 2.  
3.2.2 Cells and cell growth conditions: 
THP-1 cells: 
Human THP-1 cells were obtained from American Type Culture Collection 
(ATCC, Manassas, VA, USA) and were cultured in RPMI 1,640 media, which contained 
10% fetal bovine serum (FBS) and 1% amphotericin B/streptomycin/penicillin, 
hereinafter referred as the complete medium (CM), and were incubated at 37 °C in 
humidified ambient air with 5% CO2. Prior to experiments, THP-1 cells were grown in 
the medium for 24 hours for adaption. After 24 h, the medium was removed and replaced 





PMA-differentiated THP-1 macrophages (P-THP-1):  
THP-1 monocytes (5×105 cells/mL, 2mL) were seeded in CM in 6-well plate 
(Costar; Corning Incorporated, Corning, NY, USA). Cells were then differentiated with 
PMA (25ng/mL) for 48 hours, which were incubated at 37 °C with 5% CO2 in ambient 
air. After washing three times with PBS, attached cells were grown in fresh CM and 
ready for treatments. 
3.2.3 Total protein analysis on P-THP-1 macrophages 
Total protein of P-THP-1 was measured to determine cell growth/viability. After 
P-THP-1 cells (5×105 cells/mL, 2mL) were differentiated with 25 ng/mL PMA in 6-well 
plates for 48 hours under cover of foil, which were incubated at 37 °C with 5% CO2 in 
ambient air. P-THP-1 cells were then treated with (1, 5, 10, 25 µM) or without resveratrol 
(control, DMSO) for 48 hours. Cells were harvested and total protein was measured using 
the sulforhodamine B (SRB) assay. Cells were first fixed with trichloroacetic acid (TCA, 
10%) for one hour at 4 °C, and then stained for 20 minutes with 0.4% (wt/vol) sul-
forhodamine B (SRB) dissolved in 1% acetic acid. Unbound dye was removed by five 
washes with 1% acetic acid, and protein-bound dye was extracted with 10 
mM unbuffered Tris base (pH 10.5) for determination of optical density in a computer-
interfaced, 96-well microliter plate reader (530 nm) [111, 112].  
3.2.4 Total RNA isolation, cDNA synthesis, and gene expression analysis 
using real-time PCR  
The mRNA expression level on THP-1 and P-THP-1 cells was measured by real-
time PCR. THP-1 and P-THP-1 cells were cultured in 6-well plates treated with control 
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(DMSO), resveratrol (1, 5, 10, 25 µM), pterostilbene (Ptes) (10 µM), Genistein (Gen) (10 
µM) for 48 hours and then LPS (10 ng/mL) or Pam3CSK4 (500 ng/mL) were added for 
another 2 hours. Methods of gene expression analysis by RT-PCR are presented in 
chapter 2.2.5. The TaqMan gene expression assay was used to measure IL-1β, IL-6, IL-8, 
COX-2, MCP-1, TNF-α, CYP1A1 and CYP1B1. The mRNA levels were normalized to 
an internal control, GAPDH mRNA.    
3.2.5 IL-6 protein measurement by ELISA 
To determine IL-6 protein expression, THP-1 monocytes (5×105 cells/mL) were 
cultivated in 14-mL EP tubes overnight, and treated with DMSO, Res (1, 5, 10, 25 µM), 
Ptes (10 µM), or Gen (10 µM) for 48 hours. Medium and treatments (Res, Ptes, Gen) 
were changed every 24 hours. LPS (10 ng/mL) or Pam3CSK4 (PAM) (500 ng/mL) were 
added with previous treatment for another 4 hours. Then supernatant was collected for 
ELISA test while remaining cells were counted for normalization of quantity.  
After 48-hour of differentiation by using PMA (50 ng/mL)  to obtain the P-THP-1 
macrophages (1×106 cells/mL), Res (1, 5, 10, 25 µM), Ptes (10 µM) and Gen (10 µM) 
were added for 48 hours. Medium and treatments were changed every 24 hours. After 48 
hours, LPS (10 ng/mL) or PAM (500 ng/mL) were added with Res, Ptes and Gen for 6 
hours. Cells were collected for ELISA test, and results were normalized by total protein 
content (SRB assay) of P-THP-1 cells.  
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3.2.6 Statistics: 
Data were analyzed with GraphPad Prism 5 and are presented as means ± SE. A 
one-way ANOVA followed by post hoc analysis using the Tukey test to determine the 





3.3.1 Effect of resveratrol on the growth of P-THP-1 macrophages 
After 48 hours of incubation, Res demonstrated a dose dependent effect on the 
growth of P-THP-1 cells. Res 1 and 10 µM treated cells had a similar growth rate as the 
DMSO controls at 48 hours (b, Figure 7A). Res 5 and 25 µM were associated with a 13.2% 
increment and 14.3% reduction, respectively, in the growth of P-THP-1 cells at 48 hours 
compared to DMSO controls  (p < 0.05) (Res 5 and 25 µM, Figure 7A). The IC50 of Res 








Figure 7. Effect of resveratrol on the cell growth and IC50 in P-THP-1 macrophages. P-
THP-1 macrophages (5×105/mL) (A) were plated in 6-well plates treated with (1, 5, 10, and 25 
µM) or without resveratrol (control, DMSO) for 48 hours. Total protein content of P-THP-1 cells 
was measured by using the SRB method and was used to normalize the number of P-THP-1 cells 
after 48 hours. Fig. 7 (B) showed the half maximal inhibitory concentration (IC50) of resveratrol 
for P-THP-1. Values are expressed as the mean ± SE of 3 separate experiments. For Fig. 7 (A), 
means with different letters are significantly different (p<0.05).  
P-THP-1 cell growth
































3.3.2 Differentiation of THP-1 monocytes into macrophages by PMA 
Macrophages are considered to be a good cell model for testing in vitro anti-
inflammatory response. THP-1 monocytes can be differentiated into macrophages after 
exposure to PMA. Dr. E. K. Park [113] reported that cellular gene expression was not 
altered after exposure to low concentrations of PMA. THP-1 monocytes were incubated 
with 10, 25, and 50 ng/mL PMA for 48 hours. Flasks were covered with foil to prevent 
exposure to light.  THP-1 monocyte differentiation into macrophage was documented by 
using two methods, cell adhesion and morphology as well as expression of the 
macrophage surface marker CD 14. THP-1 monocytes were round small spherical cells 
that grow in suspension. THP-1 differentiated macrophages were slightly larger and 
adhere to the culture flask walls.  THP-1 monocytes were fully attached to the culture 
flask after differentiation using PMA 25 and 50 ng/mL. Adherent cells were examined for 
morphologic changes and CD 14 mRNA expression. There was a 30-fold increase in CD-
14 expression in THP-1 cells treated with PMA (25 ng/mL) (Figure 8), compatible with 
cell differentiation into macrophages. Both morphologic observation and CD 14 
expression confirmed the differentiation of THP-1 monocytes into macrophages. PMA 
concentrations of 25 ng/mL and treatment time of 48 hours were chosen as the optimal 




Figure 8. CD 14 is a marker for THP-1 monocyte differentiation into macrophages after 
PMA stimulation. THP-1 monocytes (5×105/ml) were differentiated by using 25 ng/mL PMA 
for 48 hours in the dark. After stimulation, total RNA was extracted from cell samples, and 1 µg 
of extracted total RNA was reverse transcribed into cDNA. Quantitative real-time PCR analyses 
were performed in triplicate.  Loading was normalized by using GAPDH as an internal control. 
THP-1 mRNA expression without PMA stimulation was normalized to a value of 1. Values were 
expressed as the mean ± SE of 3 separate experiments. * was used to indicate that the means were 

































3.3.3 CYPs gene expression 
CYP1A1 and CYP1B1 are important genes related to cellular processing of drugs. 
THP-1 and P- THP-1 cells were examined to determine if Res treatment may influence 
CYP1A1 and CYP1B1 mRNA expression. CYP1B1 expression was inhibited at doses of 
Res 5 to 25 µM in both THP-1 (Fig. 9B) and P-THP-1 (Fig. 9C) cells with reductions of 
34%-70% and 86%-90%, respectively. In contrast, CYP1A1 mRNA expression was not 
affected in THP-1 cells (Figure 9A), and was not detected in P-THP-1 cells.   
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Figure 9. Effect of resveratrol on drug metabolism gene expression in THP-1 monocytes and 
P-THP-1 macrophages, without LPS stimulation.  THP-1 monocytes (A) and P-THP-1 
macrophages (B) were treated with (1, 5, 10, 25 µM) or without resveratrol (control, DMSO) for 
48 hours. CYP1A1 and CYP1B1 mRNA expression was then measured by using quantitative RT-
PCR. Values were expressed as the mean ±SE of 3 separate experiments. Means with different 
letters were significantly different (p<0.05).  
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3.3.4 Effect of resveratrol on pro-inflammatory cytokines expression of 
P-THP-1 macrophages after stimulation with LPS or PAM stimulation, 
or without stimulation 
LPS stimulation in P-THP-1 with no Res treatment (LPS 10 ng/mL, Res 0 µM) 
(Fig. 10A) markedly increased mRNA level of IL-1β, IL-6, IL-8, MCP-1, COX-2, and 
TNF-α, as compared to controls (LPS 0 ng/mL, Res 0 µM). Resveratrol treatment, Res 1-
25 µM, exerted no additional increment in IL-1β and IL-8 mRNA levels in LPS 
stimulated P-THP-1 macrophages. In contrast, Res 5-25 µM treatments markedly reduced 
IL-6 and COX-2 levels in LPS stimulated cells. In addition, a 51.5% reduction in MCP-1 
level was only observed in the Res 25 µM LPS stimulated cells. However, Res 10-25 µM 
induced 51-55% increment in TNF-α in LPS stimulated P-THP-1 cells.  
PAM stimulation in such cells with no Res treatment (PAM 500 ng/mL, Res 0 
µM) (Fig. 10B) elevated IL-1β, IL-6, IL-8 and TNF-α mRNA levels as compared to 
controls (PAM 0 ng/mL, Res 0 µM). In PAM stimulated P-THP-1 macrophages, Res 
treatment, Res 1-25 µM, mildly depressed IL-1β and IL-8 mRNA levels, but exerted a 
progressive reduction in IL-6 mRNA levels with increases in Res level. Res treatment 
exerted no effect at Res 1-5 µM but marked increases at Res 10-25 µM on TNF-α mRNA 
level in PAM stimulated P-THP-1 macrophages. 
In control P-THP-1 macrophages, without stimulations (Fig. 10C), IL-8, COX-2 
and TNF-α mRNA expression was depressed around 50%, fairly evenly, from Res 1 to 




Effect of resveratrol on pro-inflammatory cytokine expression in P-THP-1 
macrophages after LPS stimulation 
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Effect of resveratrol on pro-inflammatory cytokine expression in P-THP-1 
macrophages after PAM stimulation 
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Effect of resveratrol on pro-inflammatory cytokine expression in P-THP-1 














Figure 10. Effect of resveratrol on pro-inflammatory cytokine expression of P-THP-1 
macrophages with or without LPS or PAM stimulation. THP-1 monocytes (5×105/mL) were 
differentiated by PMA in the dark for 48 hours. P-THP-1 macrophages were then treated with (1, 
5, 10, 25 µM) or without resveratrol (control, DMSO) for 48 hours. (A) 10 ng/mL LPS were 
added to the final cell culture for 2 hours at 37 °C. (B) 500 ng/mL were added to the final cell 
culture for 2 hours at 37 °C. (C) Control cells treated for 2 additional hours without further 
treatment. Cytokine mRNA expression was measured by using quantitative RT-PCR. Values 
were expressed as the mean ±SE of 3 separate experiments. Means with different letters were 










































































































3.3.5 Comparison of three bioactive compounds 
LPS stimulation in cells (Fig. 11A) without bioactive treatment (LPS 10 ng/mL, 
DMSO 1 µM) markedly decreased IL-1β, IL-6, IL-8, COX-2, MCP-1 and TNF-α mRNA 
levels as compared to controls (LPS 0 ng/mL, DMSO 1 µM). Resveratrol 10 µM and 
pterolstilbene (Ptes 10 µM) treatments markedly increased all mRNA expressions with 
the exception of Ptes, which exerted no effect on TNF-α. Gen 10 µM treatment also had 
no effect on these mRNA expressions. 
In contrast, in THP-1 cells not stimulated by LPS (Fig. 11B), bioactive 
compounds exerted little or no effect on mRNA expressions. The exceptions are: Res 
treatment increased IL-1β level by 67.8%; and Gen treatment depressed TNF-α level by 
43.7% as compared to DMSO controls.  
LPS stimulation in P-THP-1 macrophages (Fig. 11C), without bioactive 
treatments (LPS 10 ng/mL, DMSO 1 µM), markedly elevated mRNA level of IL-1β, IL-6, 
IL-8, COX-2, MCP-1 and TNF-α, as compared to controls (LPS 0 ng/mL, DMSO 1 µM). 
All bioactive compounds exerted no effect on IL-1β level. Most importantly, IL-6, COX-
2 and MCP-1 levels were depressed by Res and Ptes, both with inherent stilbene structure. 
Gen elevated IL-6, but had no effect on COX-2 or MCP-1. Only Ptes treatment, among 
all bioactive compounds, increased IL-8 and TNF-α mRNA level as compared to control 
DMSO treatment. 
In P-THP-1 macrophages (Fig. 11D), not stimulated by LPS, Res 10 µM 
treatment depressed mRNA level of IL-1β, IL-8, COX-2, MCP-1 and TNF-α. In addition, 
Ptes and Gen treatment only decreased mRNA level of IL-1β and COX-2, and MCP-1, 
respectively, as compared to control (DMSO 1 µM). 
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Effect of bioactive compounds on pro-inflammatory cytokine expression in THP-1 
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Figure 11. The effect of resveratrol, pterostilbene and genistein on pro-inflammatory gene 
expression in THP-1 monocytes and P-THP-1 macrophages with or without LPS 
stimulation.  THP-1 monocytes (2.5×105/mL) were cultured overnight and then treated with 
DMSO (control), resveratrol (10 µM), pterolstilbene (10 µM) or genistein (10 µM) for 48 hours. 
Cells were then stimulated with 10 ng/mL LPS (A) or control-no LPS (B) for 2 hours at 37 °C. P- 
THP-1 macrophages (5×105/mL) were treated with DMSO (control), resveratrol (10 µM), 
pterolstilbene (10 µM) or genistein (10 µM) for 48 hours. Cells were then stimulated with 10 
ng/mL LPS (C) or control-no LPS (D) for 2 hours at 37 °C. Cytokine mRNA expression of 
treated cells was measured by using quantitative RT-PCR. Values were expressed as the mean ± 
SE of 3 separate experiments. Means with different letters were significantly different (p<0.05). * 
was used to indicate means significantly different from control (p<0.01). 
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3.3.6 Effect of Resveratrol on the expression of IL-6 protein levels 
LPS and PAM stimulation in THP-1 monocytes increased IL-6 protein level as 
compared to controls (LPS/PAM 0 ng/mL) (Fig.12A and B). IL-6 protein level, in LPS or 
PAM treated THP-1 cells  (Fig.12A and B), increased progressively with Res treatment 
of Res 5 to 25 µM, or Res 10 to 25 µM, respectively.  
Similarly, LPS or PAM stimulation of P-THP-1 macrophages markedly elevated 
IL-6 protein level as compared to controls (LPS/PAM 0 ng/mL) (Fig. 12D and E). 
However, IL-6 protein level in LPS or PAM treated P-THP-1 cells (Fig. 12D and E) 
decreased from Res 10 to 25 µM or Res 5 to 25 µM, respectively. 
In bioactive compounds treated and LPS stimulated THP-1 monocytes (Fig. 12C) 
or P-THP-1 macrophages (Fig. 12F), IL-6 protein level was markedly increased or mildly 














Figure 12. Effect of LPS on IL-6 secretion in THP-1 monocytes and P-THP-1 macrophages. 
THP-1 monocytes (A, B, C) and P-THP-1 macrophages (D, E, F) were pretreated with resveratrol 
for 48 h and then stimulated with LPS for 4 h and 5 h, respectively. IL-6 secretion was measured 
by using an ELISA. Data were normalized by cell count. Bars represent the mean ± SE of three 
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3.4 Discussion  
In chapter 2, we have discussed the effect of Res on THP-1 monocytes, we found 
that Res showed low IC50 in THP-1, inhibited the cell proliferation by elevating p21 
mRNA and protein gene expression, and induced S phase and G0/G1 phase arrest with 
the Res levels (5 -10 µM), attainable by dietary consumption, and with pharmaceutical 
level (25 µM), respectively.  
Hereinbelow, the effect of Res in the two cell lines, THP-1 and P-THP-1 cells, 
will be further discussed to determine whether Res has cell type specificity. THP-1 
monocytes and P-THP-1 macrophages, derived from cancer cell lines, which are major 
cell types that play key role in chronic inflammation and also are involved in cancer, 
atherosclerosis and diabetes [114]. In our study, the influence of Res on cell proliferation 
in THP-1 and P-THP-1 cells, CYPs gene expression, pro-inflammatory cytokines and 
mediators’ gene expression was examined to determine its effect related to cancer 
prevention and chronic inflammation. Data generated from these in vitro human cell-line 
studies will aid in the design of future studies involving normal cell types and animals. 
To further study the relationship between Res structure and its effect, another 
stilbene structure compound, pterostlbene (Ptes), together with a non-stilbene compound, 
genistene (Gen), were used in a comparative study.  
Firstly, we examined the influence of Res concentration, ranging from dosages 
attainable by diet to therapeutic level, on THP-1 and P-THP-1 cells. Although P-THP-1 
macrophages were differentiated from THP-1 monocytes, they reacted differently from 
THP-1 monocytes. In other studies with cancer cell lines, Res induced variable effects on 
apoptosis and growth. In 2002, Andrew et al., [5858] reported that IC50 values for 
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apoptosis ranged from 70 to 150 µM in five human cancer cell lines (MCF7, SW480, 
HCE7, Seg-1 and HL60). Similarly, Helene et al., (2002) reported that apoptosis was 
induced in their Res treated lymphoid and myeloid leukemia cells with IC50 5-43 µM [59, 
60, 61]. In contrast, apoptosis was undetected in Res treated HL60 cells (Human 
promyelocytic leukemia cells) [62, 63]. Although the culture conditions collectively were 
different among these studies and the present studies, the available data showed that Res 
acted differently on cell proliferation and apoptosis dependent on cell types. Our results 
showed that IC50 for THP-1 monocytes and P-THP-1 macrophages treated with Res was 
17 and 76 µM, respectively, indicating that monocytes are much more sensitive than 
macrophages to resveratrol treatment.  
Data from this study also indicate that Res at levels, attainable by dietary intake, 
did not show toxicity and apoptosis in either cell line. However, Res at 25 µM induced 
apoptosis in THP-1 leukemia cells, but not in P-THP-1 macrophages. Lower 
concentrations of Res (< 10 µM), attainable by usage of dietary supplements intake, did 
not cause any apoptosis and toxicity on THP-1 and P-THP-1 cells. As shown in other 
studies, THP-1 is sensitive to cytotoxic effect of Res [115], whereas P-THP-1 
macrophages are refractory to Res [116], which are consistent with our result. From cell 
cycle results derived from THP-1 cells, Res induced anti-proliferation effect on cell 
growth with different cell cycle phase arrest in a dose-dependent manner. The effects of 
Res on cell cycle are clearly variable depending on the concentration of Res. At lower 
dosages, Res (5 and 10 µM) just induced S-phase arrest by inhibiting the proliferation of 
THP-1 without apoptosis. However, Res at 25 µM appeared to be toxic, and induced 
G0/G1 phase arrest and apoptosis in THP-1 monocytes.  
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P450 (CYP) cytochromes are enzymes that catalyze phase-I metabolism reactions, 
in which CYP1A1 and CYP1B1 are key members participating in the metabolisms of 
xenobiotics and endobiotics. CYPs, have oxygenase activity and commonly catalyze 
redox reactions, which is involved in the oxidation of the substrate and reduction of water. 
P450 1A1 (CYP1A1) catalyzes such reaction that involves in the hydroxylation of a 
vacant position of an aromatic ring on various drugs, food components or environment 
contaminants. Similar to CYP1A1, P450 1B1 (CYP1B1) activates several mutagens, like 
catalyzing the 4-hydroxylation of estrogens [117]. The two enzymes are also involved in 
the generation of superoxide radicals [118] and their expressions are enhanced in a 
diversity of tumor cells [119]. Reactions catalyzed by such enzymes are considered to 
initiate carcinogenic pathways and lead to cancer development. Inhibition of CYP1A1 
and CYP1B1 by Res was shown in several studies [120, 121, 122]. In our study, 
CYP1A1 was not modulated by Res in THP-1 cells, and was not detected in P-THP-1 
cells. Interestingly, CYP1B1 mRNA expression was decreased in both cell lines by Res 5 
and 25 µM. In 2009, Beedanagari et al., [123] reported that 10 µM Res inhibited dioxin-
induced expression of CYP1A1 and CYP1B1 at the transcription level in both human 
breast cancer cell line MCF-7 and human hepatocellular carcinoma cell line HepG2. Such 
results have also been confirmed by the research of Ciolino et al., [122]. In contrast, our 
present study demonstrated that Res inhibited CYP1A1-independent CYP1B1 mRNA 
expression in both THP-1 and P-THP-1 cells, which indicated that Res can impair cancer 
development in THP-1 and P-THP-1 cells by down-regulating CYP1B1 mRNA 
expression. In addition, together with data found in other research, Res induced dose- and 
cell-type-dependent modification on CYP1A1 and CYP1B1 gene regulations. 
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In addition, Res gradually induced several pro-inflammatory cytokines gene 
expression in LPS-induced THP-1, which is different from the findings of Oh et al., [124] 
that Res (0.1-100 µM) inhibited IL-8 production in LPS-induced THP-1 cells. However, 
the culture and treatment conditions used in their research were different from the present 
study and this may explain the conflicting findings. Oh et al., [124] pre-treated THP-1 
cells with Res for only 30 minutes, and then LPS were added for 24 hours together with 
Res. The effect of Res on THP-1 cells was too short, and LPS treatment was too long to 
examine the IL-8 mRNA expression because LPS-induced IL-8 transcripts in THP-1 cells 
have been reported to have a significantly shorter half-life (1.2 h) [125]. Moreover, Wang 
et al., [126] found that at first resveratrol delayed LNCaP tumor growth and inhibited 
expression of a marker for steroid hormone responses in xenograft mice. However, 
resveratrol exposure for longer time led to increased angiogenesis and inhibition of 
apoptosis in the xenograft. Wang’s [126] report suggested that Res might delay some 
genes transcription expression and induced the cancer promotion later. Hence, together 
with our result that Res enhance pro-inflammatory cytokines mRNA expression in THP-1 
cells on a concentration-dependent manner to enhanced inflammation, Res may have a 
delay effect on pro-inflammatory cytokines secretion. However, since Res has low IC50 
(17 µM), 48-hour treatment of Res with increasing concentrations may induce pro-
inflammation effect due to its possible toxic effect on the cells, which may be regarded as 
a harmful stress. 
On the other hand, the findings that Res can have such variable effects between 
THP-1 and P-THP-1 cells and that Res treatment induces anti-inflammation effect in P-
THP-1 macrophages is very interesting. Based on our results, Res appeared to show less 
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harm for the growth of P-THP-1 macrophages and induced inhibition on selected pro-
inflammatory cytokines with or without inflammation induction by LPS or PAM. Under 
stimuli (LPS or PAM), NF-κB pathway is responsible for the enhanced production of 
pro-inflammatory cytokines [127]. These findings suggest that Res, in a dose-dependent 
manner, can inhibit inflammation effect by partially reducing pro-inflammatory cytokines, 
MCP-1 and COX-2 in P-THP-1 macrophages. 
Interestingly, In LPS/PAM stimulated P-THP-1 macrophages, Res at 10 and 25 
µM increased TNF-α mRNA levels, which were different from the rest of the findings 
that Res inhibited IL-1β, IL-6 and IL-8 mRNA expression or did not show any effect. 
Inconsistent observation of TNF-α mRNA expression may be caused by several reasons. 
One is that the treatment time on LPS/PAM stimulated P-THP-1 macrophages did not 
show the peak mRNA expression of TNF-α expression, but showed an opposite 
expression trend. Another reason is that Res may trigger different pathway of TNF-α, IL-
1β, IL-6 and IL-8. Alternatively, Res may have up-regulated promoter gene of TNF-α 
mRNA and increased its expression in P-THP-1 cells. Our findings on the expression of 
the 4 genes in the LPS/PAM stimulated P-THP-1 cells provide limited data, and the 
inconsistent outcome needs further investigation on such signaling pathway.  
 
   
Res Ptes Gen 
 
Figure 13. Structure of resveratrol-Res (A), pterostilbene-Ptes (B) and genistein-Gen (C). 
A B C 
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By observing the effects of Res on THP-1 and P-THP-1 cell lines, we then 
investigated whether or not the effect of Res is derived from the stilbene structure. To 
further confirm this hypothesis, one stilbene-based compound, pterostilbene (Fig. 13B), 
and a non-stilbene-based compound, genistein (Fig. 13C), were selected for our study. 
From the pro-inflammatory cytokine mRNA expression results, Ptes was shown to exert 
similar effect as Res, whereas Gen showed no effects.  Data from these studies suggested 
that stilbene-structure compounds exerted anti-inflammation function in P-THP-1 
macrophages, with or without LPS stimulation, and induced inflammation in LPS-




In the present study, we aim to determine whether the effects of Res have cell 
type specificity, and whether the basic stilbene structure accounts for inducing such 
effects. Results from the present study showed that Res exerted anti-proliferation in both 
cell lines, and possibly anti-cancer function by elevating p21 gene expression and down-
regulating CYP1B1 mRNA level on THP-1 monocytes, as well as cytokine-selected pro 
or anti-inflammation effects on THP-1 or P-THP-1 cells, respectively. By further 
comparison with two other structure-specific compounds, both Res and Ptes showed 
similar effects. Our conclusion is that resveratrol exhibited cell-type- and concentration-
dependent toxicity, exhibited blocking cancer development property by down regulation 
of CYP1B1 in both cell lines, and exerted pro- or anti-inflammation effect on monocytes 
or macrophages, respectively. Results from the present study support the hypothesis that 
Res showed different effects on different cell types, and such effects are attributed to the 
basic stilbene structure.  
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Chapter 4 Future study 
Although resveratrol has been studied for more than two decades, its effects on 
innate immune cells under physiologic attainable conditions are seldom examined. In our 
study, our first aim is to determine the effect of Res (from dietary to pharmaceutical 
concentrations) in THP-1 monocytes regarding the toxicity and cancer prevention 
function. In our study, Res exhibited concentration-dependent toxicity, induced different 
cell cycle arrest on a concentration manner, exhibited blocking of cancer development 
property by inducing p53-independent p21 gene expression, which is a possible candidate 
for the potential cancer treatment.  
In the present study, we found that resveratrol exhibited cell-type- and 
concentration-dependent toxicity, exhibited blocking cancer development by down 
regulation CYP1B1 in both cell lines, and exerted pro- or anti-inflammation on 
monocytes or macrophages, respectively.  
Currently, we have examined the effect of Res with physiological attainable 
concentrations in human THP-1 monocytes and its derived P-THP-1 macrophages with 
Res. In the future, the long-term effects of daily consumption of Res can be further 
examined. In addition, normal cell lines can be used in more precise and applicable 
studies. These will then lead to animal and human studies on the effects of long-term Res 
consumption, which will generate scientific evidence needed for the establishment of 
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